13 clinically reviewed articles, written and peer-reviewed by the HealthRX.com Medical Team.
Showing 13 of 13 clinical reviews.
A complete caregiver guide to administering liraglutide (Saxenda, Victoza) to adolescents aged 12 to 17, covering injection technique, dose escalation, storage, missed doses, and safety monitoring backed by current FDA labeling and clinical trial data.
A clinician-reviewed guide to liraglutide's effects on growth, puberty, bone density, metabolism, and neurodevelopment in adolescents aged 12 to 17, with trial data, dosing guidance, and safety monitoring protocols.
How to safely transition adolescents aged 12 to 17 from pediatric to adult liraglutide care, including dose continuity, monitoring handoffs, and what the evidence says about long-term outcomes.
A complete clinical guide for teens, parents, and school nurses on managing liraglutide (Victoza/Saxenda) during the school day, sports, and extracurricular activities.
A clinician-reviewed guide to liraglutide use in adults aged 65 and older, covering physical activity, structured programs, dosing cautions, and safety monitoring in geriatric patients.
A clinician-reviewed guide for caregivers administering liraglutide to adults 65 and older, covering injection technique, dose titration, hypoglycemia risk, storage, and monitoring in home and facility settings.
A clinician-reviewed guide to off-label liraglutide use in adolescents ages 12 to 17, covering FDA approval status, trial data, dosing, safety, and how it compares to on-label alternatives.
A clinical guide for patients and providers on using liraglutide (Victoza, Saxenda) in adults aged 65+, including dosing adjustments, safety considerations, and how to manage care transitions from geriatric to adult medicine.
A clinical review of off-label liraglutide use in geriatric patients (65+), covering evidence from major trials, age-specific dosing considerations, cardiovascular data, and safety signals unique to older adults.
A comprehensive clinical review of liraglutide's developmental impact in pediatric patients under age 12, covering GLP-1 receptor biology, weight outcomes, growth data, neurodevelopmental signals, and current FDA approval status.
A clinician-reviewed guide covering how liraglutide affects school-age children under 12, including dosing schedules, injection logistics at school, physical activity guidance, and safety monitoring.
A clinician-reviewed guide covering liraglutide use in pediatric patients under age 12, current FDA approval status, dosing evidence, and how to manage the transition to adult endocrinology or obesity medicine care.
Liraglutide is FDA-approved for obesity in adolescents aged 12 and older, but its use in children under 12 remains off-label. This clinical guide covers the evidence, risks, dosing considerations, and when a specialist referral is warranted.